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Abstract
Study Objectives: Millions suffer from sleep disorders that often accompany severe illnesses such as major depression; a
leading psychiatric disorder characterized by appetite and rapid eye movement sleep (REMS) abnormalities. Melanin-
concentrating hormone (MCH) and nesfatin-1/NUCB2 (nesfatin) are strongly co - expressed in the hypothalamus and are
involved both in food intake regulation and depression. Since MCH was recognized earlier as a hypnogenic factor, we
analyzed the potential role of nesfatin on vigilance.
Design: We subjected rats to a 72 h-long REMS deprivation using the classic flower pot method, followed by a 3 h-long
‘rebound sleep’. Nesfatin mRNA and protein expressions as well as neuronal activity (Fos) were measured by quantitative in
situ hybridization technique, ELISA and immunohistochemistry, respectively, in ‘deprived’ and ‘rebound’ groups, relative to
controls sacrificed at the same time. We also analyzed electroencephalogram of rats treated by intracerebroventricularly
administered nesfatin-1, or saline.
Results: REMS deprivation downregulated the expression of nesfatin (mRNA and protein), however, enhanced REMS during
‘rebound’ reversed this to control levels. Additionally, increased transcriptional activity (Fos) was demonstrated in nesfatin
neurons during ‘rebound’. Centrally administered nesfatin-1 at light on reduced REMS and intermediate stage of sleep,
while increased passive wake for several hours and also caused a short-term increase in light slow wave sleep.
Conclusions: The data designate nesfatin as a potential new factor in sleep regulation, which fact can also be relevant in the
better understanding of the role of nesfatin in the pathomechanism of depression.
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Introduction
Nesfatin-1, the N-terminal fragment of the nucleobindin2
protein (NUCB2) is a potent anorexigen decreasing nocturnal
food intake in rodents in a dose-dependent manner [1]. Higher
plasma nesfatin-1/NUCB2 (nesfatin) levels in overweight patients
point to its role in food intake regulation also in humans [2]. In
addition, nesfatin has been associated with further functions too,
like processing emotional states, such as anxiety and stress [3,4].
Since depression, a major cause of morbidity worldwide is also
characterized by marked alterations in emotional states and
feeding, initial research on the role of nesfatin regarding this field
may have high relevance. As already has been established, patients
with major depressive disorder possess high plasma level of
nesfatin [5]. For plasma and cerebrospinal fluid nesfatin levels
positively correlate, CNS problems related to alterations in
nesfatin expression may underlie this elevation [2]. This is also
supported by the fact that nesfatin mRNA content is elevated in
the Edinger-Westphal nucleus of depressed male suicide victims
[6]. Besides emotional and feeding disturbances, sleep-wake
regulation is another function typically affected in depression
[7]. Impaired sleep continuity, decreased rapid eye movement
sleep (REMS) latency and elevated time spent in REMS are
characteristic sleep-EEG changes in depressed patients [8,9]
moreover, antidepressant medication also alters sleep. As a
consequence, the existence of a relationship between nesfatin
and sleep regulation can be assumed [10].
The largest population of nesfatin neurons in the CNS can be
found in the perifornical and lateral hypothalamic (LH) areas that
belong to the dorsolateral hypothalamus (DLH) and in the zona
incerta (ZI) [11,12]. These areas are closely associated with sleep-
wake regulation [13], and are also related to both control of
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feeding and depression [14–17]. Two main types of neurons
forming intermingled, but separate populations were identified in
this region before; the orexin and the melanin-concentrating
hormone (MCH) producing cell groups, both increasing food
intake, but acting oppositely on vigilance [18,19]. Nesfatin is
highly co - expressed with MCH, although a smaller portion of
nesfatin neurons is MCH - negative [10]. Since MCH increases
REMS [20], but unlike nesfatin, it is an orexigenic peptide, the
possible role of nesfatin-1 in the regulation of sleep has a special
interest.
Based on the facts above, in this study, we aimed to investigate
the effect of intracerebroventricularly (icv) administered nesfatin-1
on vigilance stages, like wakefulness, REMS and non-REMS. We
also raised the questions, whether selective REMS pressure
impacts expression of nesfatin, and alters activation of the nesfatin
- immunoreactive neurons in the DLH and the ZI.
To elucidate this, we performed REMS deprivation using the
classic flower pot method [20], followed or not by rebound sleep,
and determined nesfatin protein and mRNA expressions by
ELISA and quantitative in situ hybridization (ISH) method.
Finally, we analyzed the activation pattern of MCH - positive
and - negative nesfatin cell populations under the different
experimental conditions using Fos/nesfatin/MCH triple immu-
nostainings.
Materials and Methods
Ethics Statement
Experiments were performed according to the European
Communities Council Directive of 24 November 1986 (86/609/
EEC) and the National Institutes of Health ‘‘Principles of
Laboratory Animal Care’’ (NIH Publications No. 85-23, revised
1985), as well as specific national laws (the Hungarian Govern-
mental Regulations on animal studies, December 31, 1998). All
experiments were approved by the National Scientific Ethical
Committee on Animal Experimentation, and permitted by the
governement (Food Chain Safety and Animal Health Directorate
of the Central Agricultural Office, Permit Number: 22.1/1375/7/
2010). All surgery was performed under anesthesia, and all efforts
were made to minimize suffering.
Animals. Male Wistar rats (Semmelweis University, Buda-
pest, Hungary) weighing 300–350 g were used for the studies.
Animals were kept with light-dark cycle of 12:12 h (light on at
10:00 and off at 22:00, daylight type fluorescent tubes, 18 W,
approximately 300 lx) at room temperature (2161uC), and had
free access to standard rodent chow and tap water. Animals were
habituated to the conditions in the experimental room at least for
two weeks.
Experiment 1. Effects of REMS Deprivation and the
‘Rebound Sleep’ on the Expression of Nesfatin mRNA and
Protein
REMS deprivation. REMS deprivation was performed using
the flower pot method, as described earlier [20,21]. Briefly,
animals were placed on round platforms situated in the middle of a
round water tank with a surface 0.5 cm above the water level at
lights on (10:00) for 72 h. The diameter of the platforms was either
small (6.5 cm) or large (13 cm). As muscle atony is typical for
REMS, animals on the small pots fall into the water immediately
after entering REMS. Contrarily, rats on the large pots fit better
on the surface and may sleep REMS, therefore they are used as
stress controls. According to this, animals were randomly divided
into six groups. The 1st group; small (SP), and the 2nd group; large
pot (LP) kept rats, that were sacrificed after spent 72 h on the
platforms. The 3rd group; SP plus rebound (SPR), and the 4th
group; LP plus rebound (LPR) rats that, after spending 72 h on SP
or LP platforms, respectively, were transferred to their home cages
at lights on for 3h rebound sleep after which they were killed. The
5th group; home cage (HC) and the 6th group; HCR animals were
controls, kept undisturbed in their home cages, and killed at the
end of the experiment either at lights on (HC) or 3 h later (HCR),
respectively. Rats were sacrificed by decapitation (n= 7 for ELISA,
n= 9 for ISH) or perfused with 4% paraformaldehyde in 0.1 M
phosphate buffered saline, pH=7.4 (PBS) for immunohistochem-
istry (n = 5). The brains were removed and frozen on dry ice. Fixed
tissue was cryoprotected in 20% sucrose overnight before freezing.
Rats on the platforms were fed ad libitum without restriction
using a waterproof food supplier unit at a distance easy to
approach. Body weight change and food intake of rats during the
time spent on the platforms were measured.
In situ hybridization technique. The rat nesfatin-1 cDNA
(246 bp) was purchased from Invitrogen (Budapest, Hungary,
GenBank Acc: DY314804 ), cloned into a pBC KS+ vector and
verified by sequencing. The rat corticotropin - releasing hormone
(CRH) cDNA (468 bp) was kindly provided by W.S. Young 3rd,
and used as earlier described [22]. The [35S]UTP-labeled sense
and antisense riboprobes were prepared by in vitro transcription
(Maxiscript KIT), according to the manufacturer’s protocol.
Hypothalamic regions of fresh frozen brains were cut into
12 mm thick serial coronal sections in a cryostat (Leica Micro-
systems GmbH, Wetzlar, Germany). The sections were thaw-
mounted and air-dried at 37uC onto positively charged Superfrost
Plus slides (Thermo Scientific, Budapest, Hungary). Slides were
stored at 280uC until used. Hybridizations were performed
overnight in humid chambers at 55uC with 106 cpm/slide of the
[35S]UTP-labeled probes, as described earlier [4]. After this step,
sections were apposed to a BAS-MS imaging plate (Fuji Photo
Film Co., LTD., Kanagawa, Japan, NJ) for 3 days, and then data
were read out by a Fujifilm FLA-8000 Image Analyzer. Expression
levels were evaluated from the images recorded on the phosphor
imager. Mean grey values of the area of interest were measured by
using the Image J 1.32j software (Wayne Rasband; NIH, Bethesda,
MD, USA) on both sides of 4–6 sections in each animal.
Background values measured in parallel were subtracted. The
average/animal data were used for statistical evaluation.
ELISA measurements. Hypothalamic regions of fresh fro-
zen brains were cut into 300 mm thick serial coronal sections in a
cryostat (Leica). DLH with ZI was dissected by micropunch
technique [23], using a special punching needle (inner diameter of
500 mm). Tissue pellets were stored at 280uC until further
processing. Samples were homogenized in 200 ml of 0.1 M HCl/
0.3 mM aprotinin solution (Sigma-Aldrich, Budapest, Hungary) by
ultrasound sonication for 3615 seconds on ice. Then, samples
were centrifuged for 20 min at 15,300 rpm at 4uC. The
supernatants were divided into two portions and dried by a
vacuum concentrator (Savant Instruments Inc, Holbrook, NY,
USA). The first portion was reconstituted in 40 ml 0.1 M Tris
buffer (pH=8.0) and the total protein concentration was
determined by using a Lowry-based assay. The second portion
was reconstituted in 400 ml 1x sample buffer provided in the
ELISA kit and used for determining nesfatin protein concentra-
tions, by a commercially available ELISA kit (Phonix Europe
GmbH, Karlsruhe, Germany) according to the manufacturer’s
protocol.
Immunohistochemistry. Hypothalami were cut into 50 mm
thick serial coronal sections on a frigomobil (Frigomobil, Reichter-
Jung, Vienna, Austria). Immunostaining started with blocking the
endogenous peroxidase activity, using a 3% H2O2 solution
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(Sigma-Aldrich) for 15 min. Then, sections were blocked in 1%
BSA and 0.5% TritonX-100/PBS all from Sigma-Aldrich for 1 h.
The same solution was used to dilute the antibodies. Incubations
were made for 2 days at 4uC in primary antibodies and for 1 h at
room temperature, in secondary or tertiary antibodies. Sections
were washed 3 times for 5 min in PBS following each incubation
step. To block peroxidase enzyme used for visualization previous-
ly, and to prevent species cross-reactions caused by primary
antibodies raised in the same hosts, sections were microwave-
treated in 0.1 M citric-acid (pH=6.0) for 5 min after each
immunostaining [24].
Fos immunostaining was performed using rabbit anti-Fos
primary antibody (1:30,000, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) and anti-rabbit IgG polymer-HRP
(Millipore, Budapest, Hungary) secondary antibody. The immu-
nostaining was visualized by FITC-conjugated tyramide (Invitro-
gen, Budapest, Hungary). Next, sections were incubated in rabbit
anti-nesfatin (1:24,000, Phoenix Pharmaceuticals, Inc., Burlin-
game, CA, USA) and again in anti-rabbit IgG polymer-HRP
(Millipore). The second immunostaining was developed by
tyramide-conjugated Alexa Fluor 568 (Invitrogen). In case of
triple immunostainings, rabbit anti-MCH was applied (1:10,000,
Phoenix Europe GmbH), followed by incubation in biotinylated
anti-rabbit IgG as secondary antibody (1:1,000, Vector Labora-
tories, Inc., Burlingame, CA, USA) and in extravidine-peroxidase
(1:1,000, Sigma). The MCH antigen was visualized by tyramide-
conjugated biotin (Invitrogen) and Streptavidin-Cy5 (1:1000,
Jackson ImmunoResearch Europe Ltd, Newmarket, Suffolk,
UK). Sections were mounted on non-coated slides, air - dried
and coverslipped with DPX (Sigma).
Image analysis. Nesfatin - positive cell populations were
analyzed in three areas: 1) ZI, 2) LH, 3) perifornical area,
including the perifornical nucleus itself [25]. Images were captured
bilaterally using a 20X objective (S Fluor 20X/0.75, ‘/0.17,
WD1.0) on 3–5 sections per animal by a Nicon Eclipse E800
microscope attached to a Bio-Rad Radiance 2100 Rainbow
confocal scanning system by sequential scanning. Cell counts and
determination of co - localization were made using the AnalySIS
Pro 3.2 program (Olympus, Soft Imaging Solutions GmbH,
Mu¨nster, Germany), by simultaneous examination of the greyscale
images of the separated channels and the colored overlay picture.
To identify neurons in the pictures, a numbered grid of the same
size was placed over the overlay picture and the greyscale pictures
of the separated channels. Only neurons with visible cell nuclei
were counted. Percentages of nesfatin/MCH double labeled
neurons among the nesfatin positive ones, the percentages of
Fos/nesfatin within the single nesfatin and Fos/nesfatin/MCH
within the nesfatin/MCH double positive subpopulations were
calculated per animal. Data are presented as the average of the
results from 5 animals per group.
Experiment 2. Effects of Exogenously Administered
Nesfatin-1 on Vigilance
EEG measurements. Rats (n = 6) were equipped with
electroencephalographic (EEG) and electromyographic (EMG)
electrodes for EEG recordings, as described earlier [26,27].
Stereotaxic surgery was performed under 2% halothane anesthesia
(using Fluotec 3 halothane vaporizer). All efforts were made to
minimize suffering of the animals. Briefly, stainless steel screw
electrodes were implanted epidurally over the left frontal motor
cortex (coordinates: anterior-posterior (A-P): 2.0 mm from breg-
ma, lateral (L): 2.0 mm to the midline, [25] the left parietal cortex
(A-P: 2.0 mm from lambda, L: 2.0 mm) for fronto-parietal EEG
recordings, and a ground electrode was placed over the
cerebellum. In addition, EMG electrodes (stainless steel spring
electrodes embedded in silicon rubber, Plastics One Inc.,
Roanoke, VA, USA) were placed into the muscles of the neck.
At the same time, a plastic cannula was implanted into the right
lateral ventricle (coordinates: A-P: 20.8 mm to the bregma level,
L: 2.0 mm, and ventral: 4.0 mm below the skull surface). The
cannula and the EEG electrodes were anchored to the skull with
dental cement (SpofaDental a.s., Markova, Czeh Republic). A
stainless steel obturator was inserted into the guide cannula and
was kept patent until use. After surgery, rats were kept in single
cages in the recording chamber, and were allowed to recover for 7
days. Animals were then habituated to the recording conditions for
five days before experiment started by attaching them to the
polygraph using a flexible recording cable and an electric swivel,
fixed above the cages, permitting free movements. During the
recovery and the habituation period to the recording conditions,
animals were also handled daily to minimize future experimental
stress, as described earlier [28]. On the day of the experiment,
25 pmol/5 ml of nesfatin-1 dissolved in physiological saline was
injected into the lateral ventricle of rats at light onset [29]. Control
rats received 5 ml physiological saline icv. After injections, animals
returned to their home cages and vigilance was recorded for 24 h.
The placement of the cannula was verified at the end of the study
by injecting 10 nM/3 ml of angiotensin II icv. Only animals
reacting with an intensive drinking response were included in the
study.
Sleep scoring. The vigilance states were classified by Sleep-
Sign for Animal sleep analysis software (Kissei Comtec America,
Inc., USA) for 4 sec periods using conventional criteria [27,30]
followed by visual supervision of an expert scorer who was blind to
experimental treatment.
The differentiated vigilance states were the following: 1)
wakefulness; EEG is characterized by low amplitude activity at
beta (14–30 Hz), alpha (8–13 Hz) and theta (5–9 Hz) frequencies
accompanied by high or low EMG and motor activity, 2) REMS;
low amplitude and high frequency EEG activity with regular theta
waves (5–9 Hz) accompanied by silent EMG and motor activity
with occasional twitching, 3) intermediate stage of sleep (IS); a
brief stage just prior to REMS and sometimes just after it,
characterized by unusual association of high amplitude spindles
(mean 12.5 Hz) and low-frequency (mean 5.4 Hz) theta rhythm; 4)
non-REMS; slow cortical waves (0.5–4 Hz) accompanied by
reduced EMG and motor activity [27]. In sleep analysis after icv
nesfatin-1 treatment, the following vigilance parameters were
calculated: time spent in active (AW) and passive (PW) wake,
REMS, IS, as well as in light slow wave sleep (SWS1) and deep
slow wave sleep (SWS2), per hour. Additionally, specific param-
eters were calculated, namely, the number and the average
duration of episodes in REMS, IS, SWS1 and SWS2. An episode
of any vigilance stages was defined as an item lasting at least 4 sec
and not interrupted by any other vigilance stages for longer than
4 sec. Sleep fragmentation was defined as the number of wake
epochs (AW, PW) after a sleep stage (SWS1, SWS2, REM, IS).
Since despite the habituation procedure that minimized stress, the
process of icv administration disturbed daily rhythm of the
animals, the 1st h of all EEG recordings had been omitted from the
evaluation and sleep scoring, and the analysis was performed from
the beginning of the 2nd h to the end of the 6th h of passive phase.
Statistics. We used STATISTICA 7.0 program (Statsoft
Inc., Tulsa, OK, USA) to statistical analysis. Two-Way ANOVA
followed by all pairwise comparisons with Student-Newman-Keuls
Method was used for determining significance in nesfatin-
1 mRNA and protein expressions and CRH mRNA expression.
One Way ANOVA and One Way ANOVA on Ranks followed by
Nesfatin Is Involved in Sleep Regulation
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all pairwise comparisons with Tukey or Dunn’s Method was
applied to analyze morphological data as well as cumulative food
intake and body weight change. Sleep data of different vigilance
stages, summarized hourly, were evaluated by Two Way ANOVA
for repeated measures (repeated factor: time). In case of
inhomogeneous variances of the experimental groups, repeated
measures ANOVA on Ranks was performed. For post hoc analysis,
all pairwise comparisons with Tukey HSD were used. The results
are presented as mean 6 standard error of mean (SEM).
Results
Changes in Nesfatin mRNA and Protein Levels after REMS
Deprivation and Rebound
The DLH with the ZI hosts the most prominent nesfatin -
expressing cell population in the hypothalamus regarding the
number of the cells and the expression level of the peptide (Fig. 1A).
Nesfatin mRNA and protein expressions have responded for the
experimental paradigms with parallel changes. There was no
difference between HC and HCR groups, indicating that there is
little or no spontaneous switch in nesfatin expression within three
hours after the lights on (Fig. 1B,C). Nevertheless, a significant
interaction was seen between the type of the platform and level of
the rebound (nesfatin mRNA and protein measurements, pot x
rebound interaction: F(2,39) = 4.90, p,0.05 and F(2,28) = 4.10,
p,0.05, respectively). Both nesfatin mRNA and protein levels
decreased exclusively in REMS - deprived small pot kept animals,
followed by a relative increase after the three hour rebound sleep
(Fig. 1B,C). Large pot conditions (with or without rebound) did not
affect nesfatin expression (Fig. 1B,C).
Stress - Related Changes in Rats following REMS
Deprivation
CRH mRNA level in the hypothalamic paraventricular nucleus,
the centre of the stress response in the central nervous system, as
well as body weight changes and cumulative food intake, during
the 72 h spent on the platforms, were measured. Both SP and LP
kept animals showed elevated CRH mRNA levels and a negative
energy balance, compared to HC controls, indicating stress evoked
by the experimental conditions. However, there was no significant
difference between the LP and SP kept rats regarding these
parameters (Fig. 2A,B). Cumulative food intake did not change
between the groups (Fig. 2C), confirming that negative energy
balance observed was not caused by fasting on platforms.
However, animals on either type of platform spent considerable
amount of time with swimming (unpublished data), thus fur of the
animals are often wet, and this fact can also contribute to the
increased energy expenditure of LP and SP kept rats.
Activation of Nesfatin - Positive Neuronal Cell Population
Since REMS deprivation evoked very specific changes in
nesfatin level demonstrated by ISH and ELISA measurements,
morphological studies were performed on hypothalamic sections of
HC, SP and SPR animals. Rebound evoked a robust activation in
nesfatin - positive cells in each investigated area (Fig. 3). In order
to further characterize the nesfatin - producing cell population, we
used triple fluorescent immunostaining for the visualization of
nesfatin, MCH and Fos.
Co - localization of MHC and nesfatin. In home cage
controls, most of the nesfatin-immunoreactive cells co - localized
with MCH, with slight differences in the investigated areas (rate of
MCH/nesfatin co - localization: ZI: 81.961.7%, perifornical area:
66.264.8%, LH: 75.462.1%, n= 5). The experimental conditions
did not affect the percentage of nesfatin/MCH co - localization.
Neuronal activation due to the experimental
conditions. Fos positivity in the HC and SP groups did not
differ significantly from each other in any areas, although there
was a difference between the MCH - negative and positive nesfatin
populations. Nesfatin/MCH double positive neurons exhibited
minimal activation (less than 0.5%). MCH - negative nesfatin
neurons showed a substantial activity in the perifornical area,
Figure 1. Nesfatin-1/NUCB2 expression as controlled by rapid
eye movement sleep stage. A. Autoradiographic images of coronal
sections through the middle portion of the hypothalamus showing the
area of interest hybridized against nesfatin-1/NUCB2 mRNA in control
animals. The upper and the lower panels show two different rostro -
caudal levels. Distance from the bregma is indicated at bottom left in
millimeters. Asterix: fornix, LH: lateral hypothalamic area, ZI: zona
incerta, scale: 1 mm. B,C. Nesfatin-1/NUCB2 mRNA and protein levels in
the different experimental groups determined by quantitative ISH and
ELISA measurements, respectively. HC: home cage control, sacrificed
with the animals kept on platforms, HCR: home cage control ‘‘rebound’’,
sacrificed at the same time as rebound groups, SP: small pot, SPR: small
pot plus sleep rebound, LP: large pot, LPR: large pot plus sleep rebound
groups. p*,0.05 vs. all other groups, p#,0.05 vs. SP group, n = 5–9 for
B and n=4–7 for C.
doi:10.1371/journal.pone.0059809.g001
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(24.468.1% and 39.467.4% in HC and SP groups, respectively),
while in the ZI and the LH, the activity of the MCH - negative
nesfatin neurons was less than 20% in both groups.
Sleep rebound strongly activated the nesfatin/MCH double
positive neurons regardless of the area examined (ZI: 86.962.9%,
perifornical area: 78.362.7%, LH: 79.061.8%, Fig. 4). MCH -
negative nesfatin neurons were not activated by rebound sleep in
the ZI and the perifornical area, however, some activation was
detected in the LH (Fig. 4C arrowhead), (SPR: 37.664.8%,
p,0.01 vs. HC: 6.062.4% and SP: 15.063.1% groups, n= 5).
Effects of icv Administered Nesfatin-1 on Vigilance from
the 2nd to the End of the 6th Hours of Passive Phase
According to our results, icv administered nesfatin-1 signifi-
cantly increased sleep fragmentation (F(1,10) = 5.1046, p,0.05) and
caused a trend-level decrease in total sleep time (p= 0.0587)
during the five investigated hours of passive phase. Regarding the
different sleep stages, nesfatin-1 markedly diminished the time
spent in REMS (F(1,10) = 18.99, p,0.001), compared to controls.
This decrease was ca. 60% in the 2nd h, however, in the next three
hours of sleep, the fall in REMS time approached an approximate
value of 90%, while in the 6th h it was ca. 70% (Fig. 5A). Similarly,
the amount of IS showed a significant decrease being the lowest in
the 3rd h (F(1,10) = 11.04, p,0.01, Fig. 5B). The REMS and IS -
declining effect in sleep time was also apparent in the number and
the average duration of the episodes both in REMS
(F(1,10) = 10.45, p,0.01 and F(1,10) = 12.81, p,0.01, respectively,
Fig. 5C,E) and IS (F(1,10) = 7.18, p,0.05 and F(1,10) = 6.99,
p,0.05, respectively, Fig. 5D,F). Considering the time spent in
NREM sleep, a significant time 6 treatment interaction
(F(2,20) = 4.092, p,0.05) was revealed in SWS1, when repeated
measure ANOVA was performed including the 2nd, 3rd and 4th
hours only. The following post hoc test resulted in significant
increase of SWS1 regarding the 3rd and 4th h (Fig. 6A). The time
spent in SWS2 showed no alteration in any investigated hours
(Fig. 6B).
The amount of PW elevated markedly (F(1,10) = 8.955, p,0.05,
Fig. 6C), in contrast to AW, which was unchanged (data not
shown). Noteworthy, that the increase of SWS1 and PW was
parallel to the elevation of episode-numbers generally
(F(1,10) = 9.87, p,0.05, Fig. 6D and (F(1,10) = 6.46, p,0.05,
Fig. 6F, respectively), although average episode-durations of these
stages were unaffected. However, SWS2 showed no alteration
despite an increase in the number of episodes in the 4th h (Fig. 6E).
Discussion
In this study we provide evidence for the implication of the
recently identified anorexigenic molecule, nesfatin in the regula-
tion of sleep of rat. According to our results, abolishment of REMS
decreased nesfatin mRNA and protein expression in the DLH, a
prominent site of nesfatin expression implicated in vigilance,
feeding and depression [13,18,31,32], while the subsequent REMS
rebound restored these levels. We found that central administra-
tion of nesfatin-1 diminished the time spent in REMS and IS,
while increased PW and SWS1, further reinforcing its impact in
the regulation of vigilance. Very recently Jego et al. have also
established the effect of icv nesfatin-1 on sleep architecture,
although demonstrating different results [33]. The discrepancy
may be explained by the different doses they used as well as the
different timing of the icv nesfatin administration.
To abolish REMS completely, rats were kept on single
platforms surrounded by water for 72 h [20,21]. As muscle atony
is typical of REMS, animals fall into the water and awake as they
switch to REMS. Classic (one rat per cage on a single pot) and
modified (several rats per cage on multiple pots) platform methods
are widely used to abolish REMS [20,21,34,35]. Multiple
platforms were originally introduced as an alternate of single
one to reduce stress caused by mobile restriction and social
isolation [35–37]. However, even if rats are kept together from an
early age to establish social stability and avoid stress caused by
rearrangement of the social hierarchy when placed on multiple
platforms, they show the same adrenocorticotropic hormone
(ACTH), and just minimally higher corticosterone levels than rats
on single platforms [38]. Because of these reasons, and since
unique activity of MCH neurons during REMS recovery was
demonstrated firstly with the classical flowerpot method [20], we
adopted this technique.
To isolate effects of stress, LP kept animals were used as
controls. The likewise elevated CRH levels in the hypothalamic
paraventricular nucleus, the similar plasma ACTH and cortico-
sterone concentrations [35] and the negative energy balance in
both groups confirm that LP and SP animals are exposed to the
same stress conditions with comparable activity of the hypotha-
lamo - pituitary - adrenal axis. Another aspect of importance is
thermogenesis due to wet fur. SP animals get wet when fall asleep,
but LP animals also spend considerable amount of time in the
water with swimming during the deprivation procedure. Thus,
differences either in thermoregulation due to the wet fur and in the
amount of the restraint stress, are not considered as major factors
regarding the results detected only in SP animals. Furthermore,
Figure 2. Stress-related changes and energy balance of the
experimental animals. Data show significantly increased levels of
CRH mRNA in the hypothalamic paraventricular nucleus (A) and
decreased body weights (B) both in the SP and LP kept animals,
compared to HC, without difference between the above mentioned
groups. C. Cumulative food intake shows no alterations. HC: home cage
control, sacrificed with the animals kept on platforms, HCR: home cage
control ‘‘rebound’’, sacrificed at the same time as rebound groups, SP:
small pot, SPR: small pot plus sleep rebound, LP: large pot, LPR: large
pot plus sleep rebound groups. Data are shown as mean 6 SEM,
n = 10–11, p*,0.05, p**,0.01 vs. HC.
doi:10.1371/journal.pone.0059809.g002
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changes in the sleep architecture also designate large pot kept
animals as useful controls. Both LP and SP rats have been reported
to reduce SWS [37] in line with our paradigm, as some degree of
SWS1 rebound was also observed in these groups [21]. The
existence of REMS rebound in LPR animals and data of Machado
et al. [21,37] suggest that LP animals were subjected to REMS
deprivation due to stress [39], but in the SP rats, REMS ceased
totally, creating an elemental difference between LP and SP
conditions [37]. This substantial contrast is reflected in the marked
alterations of REMS architecture and connected Fos activity in the
DLH of LPR rats, compared to SPR ones [21,40]. As a
consequence, any small pot - specific observation is likely due to
the lack of REMS.
Our data suggest a striking link between nesfatin expression and
REMS. Animals in the SP group reacted with an exclusive and
remarkable decrease in nesfatin mRNA and protein levels to the
lack of REMS, while nesfatin expression of animals in the HC and
LP groups was alike. On the other hand, a significantly higher
amount of REMS rebound with longer average duration of
episodes compared to LPR and HCR groups [21] returned these
Figure 3. Effect of rebound sleep on the activity of nesfatin1/NUCB2 (nesfatin) - positive cell population. Fos (green) and nesfatin (red)
double fluorescent immunostainings showing the three investigated areas arranged in columns (left: zona incerta, middle: perifornical area, right:
lateral hypothalamic area) in rapid eye movement sleep (REMS) - deprived - sleep rebound (A–C), REMS - deprived without rebound (D–F) and home
cage kept (G–I) animals. c: capsula interna, f: fornix, scale: 100 mm.
doi:10.1371/journal.pone.0059809.g003
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values to the control levels. There was no difference between the
HC and HCR groups indicating that circadian rhythm does not
influence nesfatin expression in the first three hours of sleep after
lights on.
Since nesfatin is an anorexigen and decrease of nesfatin mRNA
level in certain hypothalamic nuclei, like the paraventricular and
the supraoptic nuclei (but not in the DLH - unpublished
observations), was established after fasting [41,42], it is important
to clarify whether negative energy balance of animals may, or may
not be responsible for the reduction of nesfatin expression. It is
noteworthy to mention that animals were not food - deprived
during the 72 h on platforms. The cumulative food intake of rats
was identical in all groups. In spite of this, both SP and LP animals
had a decreased body weight, indicating elevated energy
expenditure. However, they did not differ significantly in this
respect, and there was no change in nesfatin mRNA expression in
LP rats. Therefore, we can exclude the idea that the changes in the
nesfatin expression in the SP animals may be related to the
disturbed energy homeostasis.
To characterize both neurochemically and neuromorphologi-
cally the nesfatin - positive cell population responsible for the
observed results, we applied multiple immunostainings. Majority
of the nesfatin - expressing neurons co - expressed MCH, and
practically all MCH cells co - expressed nesfatin, in agreement
with earlier findings [10]. REMS rebound evoked Fos expression
in large percent of nesfatin neurons. Most of these nesfatin neurons
were MCH - positive confirming previous reports [20,40],
revealing a strong activation in all investigated areas. MCH -
negative nesfatin cells showed little activation in the LH and no
activation in both the ZI and the perifornical area. Since Fos is a
transcription factor, indicating ongoing transcriptional activity
[43], the appearance of Fos signal in the nesfatin - immunoreactive
neurons is also in line with our findings showing an elevation of
nesfatin mRNA and protein levels during REM rebound. The
potential role of nesfatin in REMS regulation was further
examined by analyzing the effect of the peptide administered
centrally on vigilance stages in control rats. The applied 25 pmol
dose was established according to previous studies [1,4,44]. As
animals were presumably disturbed by the icv procedure, despite
Figure 4. Participation of melanin-concentrating hormone (MCH)-positive and MCH - negative nesfatin-1/NUCB2 (nesfatin) neurons
in the sleep - wake cycle. A–C. Illustrative pictures of the lateral hypothalamic area demonstrating the results of the triple fluorescent
immunostainings for nesfatin (red), MCH (blue) and Fos (green) in a home cage kept (A), a rapid eye movement sleep (REMS) - deprived (B) and a
REMS - deprived - sleep rebound (C) animal. Nesfatin/MCH double-positive neurons are pink (arrows), MCH - negative nesfatin neurons are red
(arrowheads). Activated nesfatin/MCH neurons show white nuclei, activated nesfatin - positive, but MCH - negative neurons show yellow nuclei. Note
that majority of the MCH - positive nesfatin neurons are activated (Fos - positive, arrows) by rebound, while only a few of the MCH - negative neurons
showed Fos - positivity (arrowhead). Scale bar: 100 mm. D. Distribution of MCH - positive (N+/M+) and MCH - negative (N+/M¯ ) neurons within the
nesfatin producing cell population and percentage of activated (Fos - positive) cells after REMS deprivation followed by rebound. Data are shown as
mean 6 SEM, n = 5.
doi:10.1371/journal.pone.0059809.g004
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previous habituation [4,21], moreover, increased plasma ACTH
and corticosterone levels have been reported after icv nesfatin-1
injection in the first 30 and 60 min, respectively [4,45], we omitted
the first hour and evaluated vigilance from the beginning of the 2nd
to the end of the 6th hours of passive phase.
Centrally injected nesfatin-1 had an IS-REMS decreasing effect
lasting 5–6 hours following administration. Decrease in the
number of REMS and IS as well as the average duration of
REMS episodes seem to be involved in this effect, suggesting that
neurons both in onset and maintenance of IS-REMS may be
affected. The decline of REMS and IS was presumably
compensated by a short-lived elevation of SWS1, and we also
found a parallel increase in the amount of passive wake, and it was
prolonged. There was a tendency for decrease of total sleep time.
The mechanism of nesfatin-1’s action on vigilance stages needs
to be clarified in the future. Increase in the activity of the
ascending arousal system and/or decrease in midbrain reticular
arousal threshold by nesfatin-1 directly or indirectly, may be one
explanation. Indeed, Yoshida et al. have reported that centrally
administered nesfatin-1 induced Fos expression in noradrenergic
neurons of the locus coeruleus and serotonergic cells of the dorsal
and median raphe nuclei [45], structures known to be parts of the
brainstem arousal system [46]. However, we should not ignore
that icv nesfatin-1 has been demonstrated to cause Fos expression
also in the PVN, the nucleus of the solitary tract and the nucleus
supraopticus [45], all being related to stress and therefore, may
potentially alter sleep architecture [39,47,48].
In relationship with MCH, it is interesting to notice a
consequent opposite effect of nesfatin-1. Unlike nesfatin-1, MCH
has been shown to induce a dose-dependent increase of REMS
when centrally injected [20]. Ahnaou et al. have demonstrated
that MCH1 receptor antagonist compounds decreased REMS, IS
and SWS2, while wake stages increased [49]. Moreover, on food
intake and energy expenditure, MCH and nesfatin act also
oppositely [1,15,44]. Co - localization of MCH with other
neuropeptides having opposite effect is not unique. A high percent
of orexigenic MCH neurons co - localize with the anorexigenic
cocaine and amphetamine regulated transcript [50].
Additionally, as for synaptic action of MCH, it has a
predominantly inhibitory effect pre- and postsynaptically and
attenuates the activation of N-, L- and P/Q-type calcium
channels, while nesfatin-1 has been found to rise intracellular
Ca2+ concentrations, by stimulating Ca2+ entry via N-, L- and P/
Q-type calcium channels [12,51]. At the same time, the receptor
or receptors for nesfatin-1 have not been identified yet; therefore
the precise mechanism of nesfatin’s action remains to be
elucidated.
In summary, we revealed a close association between REMS
architecture and nesfatin expression in the DLH and the ZI, as
well as a possible negative feedback effect of nesfatin-1 on REMS,
inasmuch as there is a disinhibition of nesfatin expression by
Figure 5. Effects of intracerebroventricularly administered
nesfatin-1 on rapid eye movement sleep (REMS) and interme-
diate stage of sleep (IS). A,B. The time spent in REMS and IS per
hour, respectively in the 2nd–6th hours of passive (light) phase. C,D. The
number and -E,F- the average duration of REMS and IS episodes per
hour, respectively. Data are presented as mean 6 SEM, n = 6 per group,
p*,0.05, p**,0.01.
doi:10.1371/journal.pone.0059809.g005
Figure 6. Effects of intracerebroventricularly administered
nesfatin-1 on slow wave sleep and passive wake (PW) vigilance
stages. The time spent and the number of episodes in light slow wave
sleep (SWS1, A and D, respectively), deep slow wave sleep (SWS2, B
and E, respectively) as well as in PW (C and F, respectively), per hour in
the 2nd–6th hours of passive (light) phase. Data are presented as mean
6 SEM, n= 6 per group, p*,0.05, p**,0.01.
doi:10.1371/journal.pone.0059809.g006
Nesfatin Is Involved in Sleep Regulation
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e59809
REMS rebound in the DLH and ZI, and an inhibition of REMS
by icv nesfatin-1. Further data are needed about the role of other
nesfatin - expressing brain areas in this process that theoretically
can be related to the sleep-wake regulation. Our results confirm
earlier findings implicating the integrative role of the DLH and ZI
in the control of a wide variety of functions, like energy
homeostasis, vigilance, regulation of motor activity and reward,
as well as more recently, in mood and depression [13,14,52,53].
Sleep architecture of humans is strongly affected by several
illnesses, like narcolepsy, anorexia and depression [7,54–56].
Hence, the present findings may be relevant not only in sleep
research, but also in other studies regarding sleep related disorders.
Depression and anorexia are among those affecting the population
worldwide. Thus, the possibility that nesfatin, the anorexigenic
peptide, recently been related also to depression [5,6] may emerge
as a potential new link between these diseases and sleep
disturbances, calls for further investigation.
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